Results from an interim analysis suggest the antibody–drug conjugate alone or in combination with pertuzumab may have a role in the first-line setting
However, secondary endpoints of the TROPION-Breast01 continue to support a potential benefit of the antibody-drug conjugate in previously treated patients
Updated results from the KEYNOTE-756 trial show benefits of the chemoimmunotherapy across subgroups of patients with ER+/HER2− breast cancer
Among the presented findings, a potential role for ESR1 gene fusions was observed
The combination therapy with the CDK 4/6 inhibitor improved overall response rate compared to standard treatment
Strategies to target MTAP deletion, KRAS G12D and ESR1 mutations, and CDK4 and CDK2 further expand the landscape of precision oncology
Evidence from tailored programmes in breast cancer show that a more holistic approach is needed to support patients to find the motivation to take up an active lifestyle
Final results from the KEYNOTE-522 study confirm that the integration of pembrolizumab into the treatment regimen has the potential to transform patient management, but careful patient selection and monitoring for toxicities will be crucial
Results from the Neo-CheckRay study report an acceptable toxicity profile with the addition of a PD-L1 inhibitor to neoadjuvant chemotherapy and stereotactic body radiation therapy
Early-phase clinical trial results show promise to optimise the current standard of care by using dual-targeting agents and investigating the most effective chemotherapy backbone for PD-L1 blockade
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.